Fig. 3From: Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective studyProgression-free survival (PFS) stratified according to the neutrophil-to-lymphocyte ratio (NLR, (<3 vs. ≥3) starting from first day of eribulin monotherapy (A) or capecitabine monotherapy (B)Back to article page